Experts in dialogue The approach of upfront combination therapy in very-high risk patients is easier for physicians and a big win for patients, according to prof. Stroes and prof. Masana.
Experts in dialogue In a video on management of statin-intolerant patients, the discussants state that we are in a good position in 2021 with new options of lipid-lowering therapies for these patients.
This e-learning consists of three expert discussions in which the current situation on LDL-c guidelines implementation, barriers of LDL-c goal attainment and solutions to improve the proportion of patients achieving their target goals are discussed.
Experts in dialogue In this video, the discussants suggest to treat hypercholesterolemia in very-high CV risk patients with a similar treatment regimen as for hypertension, that is with upfront combination therapy.
Experts in dialogue For which patients should combination therapy with statin and ezetimibe directly be initiated and for whom triple therapy with PCSK9 targeted therapy or bempedoic acid?
Experts in dialogue Two lipid experts discuss what the possible barriers are for implementing guidelines and not reaching goals with regard to LDL-c and how to overcome these barriers.
Experts in dialogue In this video, prof. Mach and prof. Stroes answer the question: How are we performing in Europe with regard to LDL-c goal attainment in very high risk patients?
Experts in dialogue Is the case for LDL-c lowering sufficiently proven or is there a need for more studies? Prof. Ray and prof. Kastelein talk about this topic and exchange their views on LDL-c lowering.